Submitted by VetCell
Partners sought
VetCell, a British biotechnology spin-out from the Royal Veterinary College (RVC) that has pioneered the use of stem cell technology to treat tendinitis in racehorses, is set to launch inAmerica
The London-based company has developed a technique that uses stem cells drawn from the umbilical cord blood of foals or from adult horses’ bone marrow, to treat muscular injuries to horse’s leg tendons.
Some of the most devastating injuries and diseases of performance horses are now treatable thanks to high tech stem cell therapy. Chronic tendinitis continues to be one of the most common career-limiting injuries suffered by flat racing and jump horses. Three high-profile horses — Harchibald, Inglis Drever and Kicking King — missed this year’s Cheltenham Festival because of tendon problems. Stem cells, for the first time, offer the prospect of a return to a fully functional tendon.
Set up by researchers at the RVC in 2002 the spin-out has seen demand for its service grow rapidly and the company is currently treating about 30 horses per month for a fee of up to £2,000 per animal.
Greg McGarrell, VetCell’s Chief Executive, said: “Tendinitis is a leading cause of retirement for racehorses that the traditional veterinary profession has had a lot of difficulty treating. The treatment, which involves injecting cultured horse stem cells directly into the damaged muscle, is twice as effective as conventional therapies for muscular injuries to racehorses, which are often valued in the millions of pounds.”
The company already has customers throughout Europe and the Middle East and has licensed the technology for use inJapan , Australia , Argentina and South
Africa
Now the company is using its expertise to set its sights on a potentially revolutionary stem-cell-based treatment for human shoulder injuries that, if successful, could be worth billions of pounds.
The company is developing trials for a treatment for similar (rotator cuff) injuries in human beings, in partnership with theInstitute of Orthopaedics UK
Additional Information
VetCell is looking for collaborative partners in the areas of cellular therapeutics, musculoskeletal research and orthopaedics. They are looking for partners focusing on the cell side of their work, and particularly academic institutions with exciting IP. Also, direct investment is always particularly welcome.
Partners sought
VetCell, a British biotechnology spin-out from the Royal Veterinary College (RVC) that has pioneered the use of stem cell technology to treat tendinitis in racehorses, is set to launch in
The London-based company has developed a technique that uses stem cells drawn from the umbilical cord blood of foals or from adult horses’ bone marrow, to treat muscular injuries to horse’s leg tendons.
Some of the most devastating injuries and diseases of performance horses are now treatable thanks to high tech stem cell therapy. Chronic tendinitis continues to be one of the most common career-limiting injuries suffered by flat racing and jump horses. Three high-profile horses — Harchibald, Inglis Drever and Kicking King — missed this year’s Cheltenham Festival because of tendon problems. Stem cells, for the first time, offer the prospect of a return to a fully functional tendon.
Set up by researchers at the RVC in 2002 the spin-out has seen demand for its service grow rapidly and the company is currently treating about 30 horses per month for a fee of up to £2,000 per animal.
Greg McGarrell, VetCell’s Chief Executive, said: “Tendinitis is a leading cause of retirement for racehorses that the traditional veterinary profession has had a lot of difficulty treating. The treatment, which involves injecting cultured horse stem cells directly into the damaged muscle, is twice as effective as conventional therapies for muscular injuries to racehorses, which are often valued in the millions of pounds.”
The company already has customers throughout Europe and the Middle East and has licensed the technology for use in
Now the company is using its expertise to set its sights on a potentially revolutionary stem-cell-based treatment for human shoulder injuries that, if successful, could be worth billions of pounds.
The company is developing trials for a treatment for similar (rotator cuff) injuries in human beings, in partnership with the
Additional Information
VetCell is looking for collaborative partners in the areas of cellular therapeutics, musculoskeletal research and orthopaedics. They are looking for partners focusing on the cell side of their work, and particularly academic institutions with exciting IP. Also, direct investment is always particularly welcome.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
